You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Her2-positve Breast Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Chengdu (Pyrotinib combined with albumin-bound paclitaxel and trastuzumab)

Recruiting
  • Breast Cancer
  • Pyrotinib combined with albumin-bound paclitaxel and trastuzumab
  • Chengdu, Chengdu, Sichuan, China, China
    West China Hospital, Sichuan University
Oct 7, 2022

Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)

Not yet recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • São Paulo, Brazil
    Centro Paulista de Oncologia (Oncoclínicas)
Oct 3, 2023

HER2-low in Unresectable and/or Metastatic Breast Cancer

Not yet recruiting
  • Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
    • (no location specified)
    Nov 6, 2023

    HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

    Not yet recruiting
    • HER2 Low Breast Carcinoma
    • SHR-A1811 for injection
    • (no location specified)
    Jun 12, 2023

    Breast Cancer Female Trial (Pyrotinib and Trastuzumab)

    Not yet recruiting
    • Breast Cancer Female
    • Pyrotinib and Trastuzumab
    • (no location specified)
    Sep 11, 2023

    HER2-positive Advanced Breast Cancer Patients Treated With ADC

    Recruiting
    • Breast Cancer
    • HER2 expression of circulating tumor cells
    • Beijing, Beijing, China
      The Fifth Medical Center of PLA General Hospital
    Apr 18, 2023

    HER2-low Advanced Breast Cancer Patients Treated With ADC

    Recruiting
    • Breast Cancer
    • HER2 expression of circulating tumor cells
    • Beijing, Beijing, China
      The Fifth Medical Center of PLA General Hospital
    Apr 18, 2023

    Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Boston (Cessation of anti-HER2 treatment)

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • Cessation of anti-HER2 treatment
    • Boston, Massachusetts
    • +1 more
    Feb 9, 2023

    Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

    Not yet recruiting
    • Estrogen-receptor-positive Breast Cancer
    • +3 more
    • elacestrant, palbociclib, abemaciclib, ribociclib
    • Chicago, Illinois
      Northwestern University
    Sep 25, 2023

    Breast Cancer Trial (Trastuzumab Deruxtecan)

    Not yet recruiting
    • Breast Cancer
    • Trastuzumab Deruxtecan
    • (no location specified)
    Jul 10, 2023

    DESTINY Breast Respond HER2-low Europe

    Not yet recruiting
    • Unresectable Breast Cancer
    • +2 more
    • Trastuzumab deruxtecan
    • (no location specified)
    Jul 6, 2023

    Survival Rate of HER2-Low Breast Cancer Patients

    Completed
    • HER2 Low Breast Carcinoma
    • immunohistochemistry (IHC) and in situ hybridization (ISH) Test
    • (no location specified)
    Mar 2, 2023

    Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2

    Recruiting
    • HER2-positive Breast Cancer
    • Early-stage Breast Cancer
    • pyrotinib combined with Capecitabine
    • treatment of physician's choice
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Sep 6, 2023

    HER2-low in Metastatic Breast Cancer Patients

    Not yet recruiting
    • HER2-negative
      • (no location specified)
      Nov 9, 2023

      HER2-positive Breast Cancer Trial (Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without

      Not yet recruiting
      • HER2-positive Breast Cancer
      • Standard of Care Adjuvant Breast Radiation
      • Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
      • (no location specified)
      Jan 20, 2023

      HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)

      Not yet recruiting
      • HR+/HER2-breast Cancer
      • Standard endocrine therapy plus Apatinib
      • (no location specified)
      Jun 2, 2023

      Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

      Active, not recruiting
      • Hormone-receptor-positive Breast Cancer
      • +2 more
      • No drug
      • Cambridge, Massachusetts
        ConcertAI database
      Sep 8, 2023

      HER2-positive Advanced Breast Cancer Trial (DP303c, Trastuzumab, Vinorelbine Tartrate)

      Not yet recruiting
      • HER2-positive Advanced Breast Cancer
      • (no location specified)
      Jun 4, 2023

      Breast Cancer Trial in Xi'an (metronomic oral vinorelbine plus anlotinib)

      Recruiting
      • Breast Cancer
      • metronomic oral vinorelbine plus anlotinib
      • Xi'an, Shaanxi, China
        Xi'an International Medical Center Hospital
      Aug 27, 2023

      t Pathologic Complete Response Observed in HER2 Positive Breast

      Completed
      • HER2+ Breast Cancer
      • Rawalpindi, Punjab, Pakistan
        Rawalpindi Medical University
      Jun 26, 2023

      Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Albumin paclitaxel+trastuzumab+pyrrolitinib,

      Active, not recruiting
      • Breast Cancer
      • HER2-positive Breast Cancer
      • Zhengzhou, Henan, China
        Henan cancer hospital
      Jun 23, 2023

      Early On-treatment Transcriptional Profiling as Predictor of

      Recruiting
      • HER2-positive Breast Cancer
      • +2 more
      • Trastuzumab (neoadjuvant)
      • +2 more
      • Hospitalet de Llobregat, Barcelona, Spain
        Institut Català d'Oncologia l'Hospitalet
      Jun 12, 2023

      HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))

      Not yet recruiting
      • HER2-positive Breast Cancer
      • Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
      • (no location specified)
      Jul 20, 2023

      HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)

      Not yet recruiting
      • HER2-positive Breast Cancer
      • 68Ga/131I-SGMIB-5F7
      • Shanghai, China
        Huashan Hospital
      Aug 1, 2023

      HER2-positive Breast Cancer, LMD Trial (Tucatinib 150 MG, Trastuzumab, Capecitabine)

      Not yet recruiting
      • HER2-positive Breast Cancer
      • LMD
      • Tucatinib 150 MG
      • +3 more
      • (no location specified)
      Aug 24, 2023